US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
GlaxoSmithKline has booked a 36 percent rise (14 percent at constant exchange rates) in core profit to £7.8 billion for 2016, driven by a 17 percent leap (6 percent at CER) in revenues to £27.9 billion.